Andrea DiFabio - 07 Nov 2022 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Legal Officer
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
07 Nov 2022
Net transactions value
$0
Form type
4
Filing time
09 Nov 2022, 16:04:54 UTC
Next filing
14 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Award $0 +135,000 $0.000000 135,000 07 Nov 2022 Common Shares 135,000 $34.77 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on the one year anniversary of the grant date, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.